| Species |
Human |
| Protein Construction |
TEM1/cd248 (Gln18-Leu687)_x000D_
Accession # Q9HCU0-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TEM1/cd248, His, Human at 1μg/ml (100μl/Well) on the plate can bind AntiTEM1 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
72.7 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 115-140 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Colorectal cancer (CRC) is one of the most common cancers worldwide usually diagnosed in the advanced stage. The serum concentration of tumor endothelial marker 1 (TEM1) was measured and correlated with clinicopathological features to evaluate whether TEM1 might serve as a biomarker for early CRC diagnosis, progression, and prognosis. TEM1 can act as a potential diagnostic, progression, and prognostic serum biomarker for patients with CRC; TEM1 might be a good supplement for commonly used markers CEA and Ca 19-9. |
| Synonyms |
Endosialin; CD248; CD164L1; TEM1; CD164 sialomucin-like 1; CD164L1; CD248 molecule; MGC119479 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
